Press Releases Archives - Immusoft

Investors & Media

Press Releases

Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026

May 6, 2026

Immusoft
Press Releases

Immusoft Announces Presentation of World’s First Patient Treated with an Engineered B Cell Therapy at Workshop Co-Hosted by FDA and ARM

April 8, 2026

Immusoft
Press Releases

Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine

March 30, 2026

Immusoft
Press Releases

Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II

January 26, 2026

Immusoft
Press Releases

Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease

December 15, 2025

Immusoft
Press Releases

Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I

October 21, 2025

PR Newswire
Press Releases

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I

October 7, 2025

Immusoft
Press Releases

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial

May 13, 2025

PR Newswire
Press Releases

Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025

January 27, 2025

PR Newswire
Press Releases

Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial

September 23, 2024

Immusoft